Syndax Pharmaceuticals Inc (SNDX) Form 8-K — Jun 10, 2026
Syndax Pharmaceuticals held its 2026 Annual Meeting of Stockholders on June 10, 2026, where stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan. The 2026 Equity Incentive Plan authorizes the issuance of up to 17,134,916 shares, comprising 7.2 million new shares and up to 9.9 million returning shares from the expired 2015 Plan. The vote on the 2026 Equity Incentive Plan was competitive, with 33,333,263 votes in favor and 25,392,051 votes against, indicating significant shareholder scrutiny on dilution. Despite the close vote, the plan passed, allowing the company to continue granting equity awards to employees, directors, and consultants.
Key figures
- Espp shares
- 500,000
- Say on pay for
- 55,688,039
- Equity plan for
- 33,333,263
- Equity plan shares
- 17,134,916
- Say on pay against
- 2,985,350
- Equity plan against
- 25,392,051
- Returning shares cap
- 9,934,916
- New shares authorized
- 7,200,000
- Total votes cast directors legault
- 58,759,463
- Total votes cast directors metzger
- 58,762,863
Price after filing
Close on the filing date to close N calendar days later (from $17.58). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.